4//SEC Filing
Lyssikatos Joseph P 4
Accession 0001415889-25-022648
CIK 0001672619other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 6:46 PM ET
Size
7.6 KB
Accession
0001415889-25-022648
Insider Transaction Report
Form 4
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Transactions
- Sale
Common Stock
2025-08-21$20.01/sh−7,500$150,099→ 940,188 total(indirect: See footnote) - Sale
Common Stock
2025-08-19$19.62/sh−5,000$98,118→ 947,688 total(indirect: See footnote)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $19.0925 to $20.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
- [F4]This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001967150
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 6:46 PM ET
- Size
- 7.6 KB